Viewing data from:

RIFAMPIN

ANDA

RIFAMPIN | A064150 | EPIC PHARMA LLC

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-08-26 | 4 NDCs

Highest NADAC/Unit

$0.8035

per ea

Lowest NADAC/Unit

$0.6802

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
42806080130RIFAMPIN 150 MG CAPSULE	$0.8035	EA	Generic	—	2026-08-19
24658080130RIFAMPIN 150 MG CAPSULE	$0.8035	EA	Generic	—	2026-08-19
42806079960RIFAMPIN 300 MG CAPSULE	$0.6802	EA	Generic	—	2026-08-19
24658080260RIFAMPIN 300 MG CAPSULE	$0.6802	EA	Generic	—	2026-08-19

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 2 NDCs (2 FSS)

Lowest Price

$89.94

Highest Price

$252.72

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
24658-0801-30RIFAMPIN 150MG CAP	$89.94	FSS	Puracap Laboratories, LLC, dba Blu Pharmaceuticals	12/31/2030
24658-0802-60RIFAMPIN 300MG CAP	$252.72	FSS	Puracap Laboratories, LLC, dba Blu Pharmaceuticals	12/31/2030

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain4 active DMFs5 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

LUPIN LTDRIFAMPIN USP

DMF 132141998

EUROAPI ITALY SRLRIFAMPIN, USP

DMF 133831998

CKD BIO CORPRIFAMPIN

DMF 136631998

OLON SPARIFAMPIN

DMF 137961998

SYNTHO RIFA PVT LTDInactiveRIFAMPIN

DMF 76031988

SOLCHEM ITALIANA S P AInactiveRIFAMPIN

DMF 100271992

NOVARTIS PHARMACEUTICALS CORPInactiveRIFAMPIN

DMF 133981998

SICHUAN LONG MARCH PHARMACEUTICAL CO LTDInactiveRIFAMPIN

DMF 136441998

FERMIC SA DE CVInactiveRIFAMPIN

DMF 137171998

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Mar 10, 2011	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 300MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: May 28, 1997

No patent or exclusivity listings for this strength.

#002 — 150MG

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Jan 2, 1998